Sareum Holdings (SAR)

 

SAR Share PerformanceMore

52 week high1.1500 11/10/17
52 week low0.7000 29/11/17
52 week change -0.0550 (-6.29%)
4 week volume139,745,214 31/03/18
price0.8200
price date1524738879
close0.8250

Latest NewsMore

Sareum to Present at BioTrinity 2018 in London

RNS Number: 8341L Sareum Holdings PLC 24 April 2018 (AIM: SAR) 24 April 2018 Sareum Holdings PLC ("Sareum" or the "Company") Sareum to Present at BioTrinity 2018 in London Sareum Holdings plc (AIM:SAR) , the specialist cancer drug discovery and development business , will present at BioTrinity 2018 in London today, at 12.20pm. Dr Tim Mitchell, CEO o...

AACR 2018 Update

RNS Number: 1966L Sareum Holdings PLC 17 April 2018 (AIM: SAR) 17 April 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum Notes that Sierra Oncology will Present Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARP Inhibitors at the AACR 2018 Annual Meeting Two posters reporting activity for SRA737 with PARP...

Late-breaker abstract for SRA737 accepted for AACR

RNS Number: 7737H Sareum Holdings PLC 15 March 2018 (AIM: SAR) 15 March 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum notes Sierra Oncology announcement that a late-breaking abstract reporting SRA737 preclinical activity in CCNE1-driven and PARP inhibitor-resistant cancers has been accepted for AACR 2018 Annual Meeting S...

Interim Results

RNS Number: 4750H Sareum Holdings PLC 13 March 2018 (AIM:SAR) 13 March 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") HALF-YEARLY RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2017 Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announces its half-yearly results for th...

Sierra Oncology expands SRA737 development program

RNS Number: 1099G Sareum Holdings PLC 27 February 2018 (AIM: SAR) 27 February 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum notes that Sierra Oncology has significantly expanded its clinical development programme for SRA737 Ongoing SRA737 clinical studies expanded to target aggregate enrolment of 200 patients across ten canc...

Preclinical synergy of sra737 and PARP inhibitor

RNS Number: 5858F Sareum Holdings PLC 22 February 2018 (AIM: SAR) 22 February 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum notes that Sierra Oncology will report preclinical data demonstrating SRA737 Synergy with PARP inhibitors at the AACR 2018 Annual Meeting Sareum Holdings plc (AIM: SAR), the specialist cancer drug di...

Notice of Interim Results

RNS Number: 6349E Sareum Holdings PLC 13 February 2018 (AIM: SAR) 13 February 2018 Sareum Holdings plc ("Sareum" or "the Company") Notice of Interim Results Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, announces that it expects to release its interim results for the six months to 31 December 2017 in the f...

Issue of Options

RNS Number: 9211Z Sareum Holdings PLC 20 December 2017 (AIM: SAR) 20 December 2017 SAREUM HOLDINGS PLC ("Sareum" or the "Company") Issue of Options The Company announces that it granted on 19 December 2017 the following share options (the "Options") to Dr Tim Mitchell, Chief Executive Officer, Dr John Reader, Chief Scientific Officer and ...

Fundamental DataMore

P/E ratio41
EPS0.02
Dividend yield0 %

Latest discussion posts More

  • Well worth reading

    https://www.biocentury.com/biocentury/regulation/2017-12-15/how-fda?s-regenerative-medicine-framework-puts-us-japan-and-
    17-Dec-2017
    fredd1eboy
  • Re: Good progress & maiden profits

    http://uk.advfn.com/p.php?pid=chartscreenshotshow&u=CTcwOoFJTTlWkejW+geWUhtoFp3NOSgnWPFmM8wjkZQ= Posted this chart in October - been waiting for 0.75p entry price since then ...
    16-Nov-2017
    KALAN
  • Re: Another 200% up....

    Cornhill had this for a week .
    15-Nov-2017
    Ripley94

Users' HoldingsMore

Users who hold Sareum Holdings also hold..

Codes & Symbols

ISINGB00B02RFS12
SymbolsSAR, LSE:SAR, SAR.L, SAR:LN, LON:SAR, XLON:SAR